Analysis · Global
THC and CBD for Dementia Agitation: What the LiBBY Trial Actually Found
A controlled trial found that a precise THC/CBD formulation reduced agitation in advanced dementia. The result deserves attention—and careful limits.
Evidence · Access · Rights
Latest stories
Reporting and analysis, newest first.
Analysis · UK
Medical Cannabis in Hospital Should Not Depend on Your Postcode
Devon’s new inpatient procedure is welcome, but Cornwall already had a public pathway. The real story is why the NHS still lacks a consistent national standard.
Analysis · UK
The UK’s Medical Cannabis Review Is Due. Here Is What It Must Answer
The Government said the ACMD’s review of medical-cannabis legislation was expected in summer 2026. As publication is awaited, these are the tests that should define its value.
Analysis · UK
What One Fire Service’s Drug-Testing Policy Gets Right
An Essex fire-service disclosure offers a rare look inside a safety-critical drug-testing policy—and shows why a positive result should begin a medical review, not end one.
Analysis · Global
Brazil’s New Medical Cannabis Rules Choose Access With Conditions
Brazil’s regulator has clarified a revised pathway for manufacturing and importing medical cannabis products. The model protects access, but keeps the category deliberately temporary.
Analysis · Global
The RESONANCE Trial Asks a Better Question About Cannabis and Cancer
A newly published trial protocol will test whether medicinal cannabis improves quality of life and symptom control in advanced cancer. It is promising research, not a result.
Analysis · UK
Can CBD Oil Trigger a Drug Test? What the Evidence Actually Says
A new systematic review finds that pure CBD is not the main problem. Undeclared THC, inconsistent products and blunt testing policies are where the real risk sits.
Analysis · UK
Medical cannabis and driving: why the UK’s THC rules face scrutiny
Medical cannabis patients can face uncertainty because THC may remain detectable after impairment has passed. The law provides a medical defence, but patients and clinicians continue to call for clearer, evidence-led rules.
Review · UK
Storz & Bickel Mighty+ Review: The Medical Cannabis Vaporiser UK Clinics Actually Recommend
The Mighty+ is the closest thing UK medical cannabis has to a reference vaporiser. We break down what makes it the clinic standard — and whether the £300 price tag is justified for patients.
Analysis · UK
Medical Cannabis in the Workplace: Your Rights as a UK Patient
Being a prescribed cannabis patient and an employee should not be incompatible. But UK employment law has yet to catch up with medical reality. Here's what patients need to know about their rights, their risks, and how to navigate disclosure.
Briefing · UK
The Week in Cannabis — 19-06-2026
The Ganja Club Weekly Digest This week, the most significant development in medical cannabis comes not from a clinical trial or a regulatory filing, but from the voices of patients themselves. A growing body of evidence suggests that lived experience is proving a more powerfu...
Guide · UK
Best Vaporisers for UK Medical Cannabis Patients (2026): The 5 That Actually Deliver
From the clinic-grade Mighty+ to the budget-friendly XMAX V3 Pro, we tested the five dry-herb vaporisers that UK patients actually rate. Not a single conduction pen made the cut.
Guide · UK
Medical Cannabis in Birmingham (2026): Clinics, Eligibility & What Patients Should Know
Birmingham is the UK's second city, and its residents have full access to every UK cannabis clinic. Here is how the system works, which clinics serve the Midlands, and what your first step should be.
Guide · UK
Medical Cannabis in London (2026): Clinics, Eligibility & What Patients Should Know
London has more prescribing clinics than anywhere else in the UK — but most Londoners still do not know medical cannabis is legal. Here is how the system works in the capital, which clinics serve London patients, and what your first step should be.
Guide · UK
Medical Cannabis in Manchester (2026): Clinics, Eligibility & What Patients Should Know
Manchester patients can access every UK cannabis clinic via video consultation — no travel required. Here is how the system works, which clinics best serve the North West, and what your first step should be.
Analysis · Europe
Europe Turns Green: How EU Cannabis Reform Momentum Is Reshaping the Continent
From German pilot programmes to Czech legalisation and French medical trials, European cannabis reform is accelerating. We examine the patchwork of policies reshaping access across the continent.
Analysis · UK
Bridging the Gap: Why Medical Cannabis Access Still Fails Patients Who Need It Most
Eight years after legalisation, the gap between policy and practice in UK medical cannabis has never been wider. We examine the cost, geography, and bureaucracy that keep patients from the treatment they are legally entitled to.
Analysis · UK
UK Cannabis Licensing Reform: What the 2026 Home Office Review Means for Patients
The Home Office has launched a review of medical cannabis licensing that could reshape how UK patients access treatment. Here is what the proposed reforms mean for patients, clinics, and the future of medical cannabis in Britain.
Review · UK
Storz & Bickel VENTY Review: The Most Powerful Portable Vaporiser They Have Ever Made
The VENTY is Storz & Bickel's newest and most powerful portable vaporiser — 20-second heat-up, adjustable airflow, and a 130-watt heater in your hand. We put it through its paces for medical cannabis patients.
Analysis · UK
From Stigma to Acceptance: How UK Cannabis Culture Is Shifting
Five years ago, telling your employer you had a cannabis prescription was unthinkable for most patients. Today, something is changing — in workplaces, in families, in the public conversation. The shift is slow, uneven, and real.
Analysis · Global
The Environmental Cost of Cannabis Cultivation
As the global cannabis industry expands, so does its environmental footprint. Indoor cultivation is energy-intensive, water use is high, and packaging waste is mounting. Can the industry's growth be reconciled with its environmental responsibilities?
Review · UK
Storz & Bickel Volcano Hybrid Review: The Desktop Vaporiser That Defined a Category
The Volcano Hybrid is the clinical gold standard for desktop vaporisers. At £500+, it is a serious investment — here is what you are actually paying for and whether it makes sense for a UK medical cannabis patient.
Analysis · UK
Medical Cannabis and Cancer: Access, Evidence, and Patient Rights
Cancer patients represent one of the largest groups seeking prescribed cannabis in the UK. The evidence for symptom management is strong. The evidence for anti-tumour effects is not. Here's what patients and families need to understand.
Analysis · Global
Cannabis and Sleep: What the Research Actually Shows
Sleep disturbance is one of the most common reasons patients cite for using medical cannabis. The research paints a complex picture: cannabis can help you fall asleep faster, but it may also alter sleep architecture in ways that matter.
Review · UK
Storz & Bickel Crafty+ Review: The Pocket-Sized Medical Vaporiser That Punches Above Its Weight
The Crafty+ is the smallest and most affordable Storz & Bickel portable — same vapour quality as the Mighty+ in a genuinely pocketable body. We review it for UK medical cannabis patients who need portability without compromise.
Analysis · UK
Project Twenty21 at Five Years: Has It Delivered?
Launched in 2020 to build the UK's largest body of evidence on medical cannabis, Project Twenty21 aimed to enrol 20,000 patients by 2021. Five years on, what has the project achieved — and where has it fallen short?
Analysis · UK
Driving and Medical Cannabis: What UK Law Actually Says
The legal position on driving with prescribed cannabis is more nuanced than 'don't do it.' UK patients have a statutory medical defence — but the reality on the roadside is more complicated. Here's what you need to know.
Analysis · Europe
Cannabis Europa 2026: The Continent Accelerates as the UK Stands Still
At Cannabis Europa London 2026, held in May, delegates confronted a stark divide: the EU races toward regulatory harmonisation and adult-use reform, while the UK remains mired in a stalled medical programme. Investment is flowing east, and the conversation has shifted from ‘if’ to ‘when’ for adult-use in countries like the Czech Republic and the Netherlands.
Analysis · UK
Medical Cannabis Patients Speak: Real Stories from UK Clinics
Behind every prescription is a person who exhausted every other option. Three UK medical cannabis patients share their journeys through conventional medicine, stigma, and finally — relief.
Analysis · Global
Beyond THC and CBD: The Minor Cannabinoids Reshaping Medicine
THC and CBD dominate the conversation, but cannabis contains over 100 cannabinoids. CBG, CBN, CBC, and THCV are emerging as therapeutic compounds in their own right. Here's what the research tells us so far.
Analysis · UK
The Real Cost of Private Medical Cannabis in the UK
Private cannabis treatment isn't cheap, but the numbers might surprise you. From consultation fees to monthly prescription costs, here's what UK patients actually pay — and where the system could do better.
Analysis · UK
CQC Scrutiny Is a Test UK Medical Cannabis Clinics Should Welcome
Private clinics widened access where the NHS did not. Their long-term credibility now depends on transparent oversight and consistently good care.
Analysis · UK
The UK Medical Cannabis Market: Growth, Challenges and the Road Ahead
The UK medical cannabis market is expanding rapidly, but significant barriers remain for patients. A comprehensive look at where things stand in May 2026.
Analysis · UK
Patient Experiences: Navigating Stigma in the UK Healthcare System
Patients report that stigma around cannabis as medicine remains one of the biggest challenges — often within the healthcare system itself.
Analysis · USA
Green Gold Rush: US Medical Cannabis Market on Track to Surpass $45 Billion by 2027, Q1 2026 Report Reveals
Q1 2026 data projects US medical cannabis market to exceed $45 billion by 2027, with record sales but price compression squeezing multi-state operators in mature western states.
Analysis · Global
Global Cannabis Reform Roundup: Policy Changes Across the World
From Germany to Brazil, the global cannabis reform landscape is shifting rapidly. A roundup of the major policy developments you need to know.
Analysis · UK
Welcome to The Ganja Club — The Story So Far
Why we're here, what we stand for, and what you can expect from this publication. Medical cannabis news, analysis, and the culture that connects the community.
Analysis · UK
Inside the UK's Underground Cannabis Community: A New Kind of Culture
Beyond the clinics and the headlines, a new cannabis community is taking shape across the UK — one built on education, peer support, and shared experience.
Analysis · Global
Key Cannabinoid Research Studies to Watch in 2026
From pain management to mental health, the clinical research pipeline for cannabinoid medicines is more active than ever. Here are the studies to watch.
Analysis · UK
NHS Prescribing: Why Medical Cannabis Remains Out of Reach for Most Patients
Eight years after the law changed, NHS prescribing of cannabis-based medicines remains negligible. Here's what's blocking progress.
Analysis · Europe
What the UK Can Learn From Germany's Medical Cannabis Model
Germany's medical cannabis system has expanded rapidly since 2024 reforms. The UK could learn valuable lessons from its European neighbour.
Analysis · Global
CBD for Anxiety: Promise Is Still Running Ahead of Proof
Clinical research offers encouraging signals, but different conditions, doses and study designs make broad claims about CBD and anxiety premature.
Analysis · UK
The NHS Access Campaign Is Really a Test of Patient Equality
The strongest case for NHS reform is not automatic prescribing; it is a fair clinical assessment that does not depend on a patient's income.
Analysis · UK
Culture Shift: How London's Cannabis Scene Is Evolving
From private members' clubs to patient meetups, London's cannabis culture is maturing. A look at the community behind the medicine.
Analysis · Global
THC and Chronic Pain: The Evidence Is Growing, but the Caveats Matter
THC-based medicines may help some people with chronic pain, but variable benefits, side effects and limited long-term data demand a measured reading.
Analysis · Europe
European Medical Cannabis Market Breaks €2 Billion Barrier in 2026
The European medical cannabis market has surpassed €2 billion in annual revenue for the first time, driven by surging demand in Germany, the UK, Poland, and Italy. With domestic cultivation scaling up and insurance reimbursement expanding, the sector is poised for continued growth into 2027.
Analysis · UK
Home Office Review: Why Cannabis Scheduling Remains a Political Flashpoint
The Home Office's position on cannabis scheduling continues to draw criticism from clinicians, researchers, and patient groups.
Analysis · UK
How to Access Medical Cannabis Through a Private UK Clinic
A practical guide to accessing medical cannabis through a private UK clinic — what to expect, how much it costs, and how to choose a clinic.
Analysis · Global
Beyond THC and CBD: The Emerging Science of Terpenes
Terpenes — the aromatic compounds in cannabis — are emerging as a key area of research with potential therapeutic applications.
Analysis · USA
First Light in the First State: Delaware Launches Adult-Use Cannabis Sales, Becoming 25th Market
Delaware became the 25th US state to legalise adult-use cannabis sales on 15 April 2026, with three retailers opening under a social equity-focused licensing programme.
Analysis · UK
Medical Cannabis and Anxiety: What the Evidence Shows
Anxiety disorders affect one in six UK adults. For some, prescribed cannabis provides relief where SSRIs and therapy have fallen short. The clinical evidence is more nuanced than advocates or sceptics tend to admit.
Analysis · Europe
Germany’s Cannabis Experiment: One Year On from the Regional Pilot Programmes
A year after Germany launched its second pillar of adult-use cannabis reform, the regional pilot programmes are yielding mixed results. Home cultivation and social clubs have found their feet, but commercial supply chains face regulatory hurdles that offer key lessons for the rest of Europe.
Analysis · USA
Landmark Bipartisan Bill Aims to Expand Medical Cannabis Access for US Veterans
Bipartisan legislation and a $25 million VA funding push could finally allow doctors to recommend medical cannabis to veterans in legal states.
Analysis · Europe
Prague’s Green Signal: Czech Republic Charts Its Own Path to Adult-Use Cannabis Regulation
In early 2026, the Czech Republic unveiled draft legislation for a regulated adult-use cannabis market, drawing inspiration from Germany’s model while tailoring provisions to local priorities. The move, paired with a major expansion of the medical programme, is reshaping Central Europe’s cannabis landscape and setting a potential timeline for legal sales by late 2027.
Analysis · UK
How to Talk to Your GP About Medical Cannabis
Raising medical cannabis with a GP can feel daunting. Many patients report being dismissed or met with silence. Here's how to approach the conversation with confidence, evidence, and a clear record of what you've already tried.
Analysis · USA
SAFE Banking Act Revived in US Senate with Bipartisan Push and 280E Reform Amendment
The SAFE Banking Act has been reintroduced in the US Senate with a key Section 280E reform amendment, advancing through committee hearings with bipartisan support.
Analysis · UK
The Endocannabinoid System: Your Body's Hidden Regulator
Every human body runs on a molecular signalling network most people have never heard of. The endocannabinoid system regulates sleep, mood, appetite, pain, and immune response — and medical cannabis works because it speaks the same chemical language.
Analysis · USA
FDA Unveils Long-Awaited CBD Regulatory Framework, Sparking Industry Debate
FDA releases March 2026 draft guidance on hemp-derived CBD, proposing a 20 mg daily cap and strict labelling rules for a $4B+ market.
Analysis · USA
DEA Cannabis Rescheduling Hearings Begin: Historic Shift Looms as Schedule III Debate Intensifies
DEA hearings in March 2026 weigh historic move of cannabis to Schedule III, with HHS and DEA officials clashing over medical use and public health risks.